NCT07669506已完成3 期
Phase III Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NuvastaticTM in Reducing Cancer-Related Fatigue in Breast Cancer Patients Undergoing Chemotherapy
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 180
- 试验地点
- 7
研究概览
简要总结
The goal of this clinical trial is to determine whether Nuvastatic™ can reduce cancer-related fatigue and improve quality of life in adult female patients with breast cancer undergoing standard chemotherapy.
The main questions it aims to answer are:
Does Nuvastatic™ reduce cancer-related fatigue as measured by change in the Brief Fatigue Inventory (BFI) from baseline to end of treatment? Does Nuvastatic™ improve quality of life, safety outcomes, and clinical parameters compared with placebo during chemotherapy?
Researchers will compare patients receiving Nuvastatic™ plus standard chemotherapy with patients receiving placebo plus standard chemotherapy to see if Nuvastatic™ leads to greater reductions in fatigue, improved quality of life, and acceptable safety while undergoing treatment.
Participants will:
- Receive Nuvastatic™ or matching placebo as a 1000 mg effervescent sachet taken three times daily after meals for three chemotherapy cycles
- Continue their standard-of-care chemotherapy as prescribed by their treating physician
- Complete fatigue and quality-of-life questionnaires (BFI, SF-36, EORTC QLQ-C30)
- Undergo routine clinical assessments, laboratory tests, ECGs, and safety monitoring
- Undergo CT imaging for tumor response assessment according to RECIST 1.1
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Supportive Care
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Female Patients aged ≥ 18 years and ≤65 years who are willing to voluntarily provide consent for participation in the study.
- •Confirm diagnosis of Breast cancer as per the available Report.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 at Screening.
- •The patient has stable haemoglobin (≥ 9 g/dL) throughout the screening.
- •Life expectancy ≥ 6 months, as per Investigator's judgment
- •Patients with co-morbidities or medical conditions including Type 2 DM, hypertension and are deem stable by the investigator can be included in the study
- •At screening patient with stable fatigue, has a newly developed fatigue OR worsening of fatigue scoring as assessed by BFI should be included.
排除标准
- •Patients who have any untreated reversible medical condition which may cause fatigue (e.g. major metabolic or electrolyte disturbance, active infection, endocrine abnormalities) as per the Investigator's clinical judgement.
- •Patient who have stage IV Disease
- •Female patients who are pregnant or breast-feeding.
- •Patients with known hepatitis C virus, hepatitis B virus, HIV infection.
- •Patients who have nausea and vomiting or any gastrointestinal disorder that is severe enough to interfere with study drug absorption in the opinion of the Investigator.
- •Patients with uncontrolled pain, who in the opinion of the Investigator are not eligible for the study. '
- •Patients with planned therapy or treatment with another investigational agent.
- •Previous exposure to any investigational agent within 4 weeks prior to screening, or planned administration of an Investigational agent, other than as specified by this protocol, during the study period.
研究者
研究点 (7)
Loading locations...
相似试验
撤回
3 期
Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired PneumoniaCommunity-Acquired Pneumonia (CAP)Acute Respiratory Distress Syndrome (ARDS)LymphopeniaImmunoparalysisSepsisNCT07492875ImmunityBio, Inc.10
招募中
2 期
Effect of Postbiotics on Microbiota and Systemic Immunomodulation of Pembrolizumab as First-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (RM HNSCC)NCT07485296Gruppo Oncologico del Nord-Ovest45
尚未招募
2 期
Phase IIa Clinical Trial of YN001 in Patients With Atherosclerotic Cardiovascular and Cerebrovascular Diseases and Erectile DysfunctionErectile DysfunctionNCT07311330Beijing Inno Medicine Co., Ltd.40
进行中（未招募）
3 期
Efficacy and Safety of LP-003 Injection in Patients With Moderate to Severe Seasonal Allergic RhinitisNCT07291284Longbio Pharma546
尚未招募
3 期
A Study of MG-K10 in Chronic Spontaneous UrticariaChronic Spontaneous Urticaria (CSU)NCT07546487Shanghai Mabgeek Biotech.Co.Ltd226